Clinical Trial Update: Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor [Phase 2]

View source ↗

Summary

Phase 2 randomized multicenter trial evaluating SU11248 (sunitinib) in platinum-refractory epithelial ovarian cancer and peritoneal cancers, assessing dosage, t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Peritoneal Cancer
• Platinum-refractory Epithelial Ovarian Cancer

Drugs mentioned

• Sutent (sunitinib)

Snippet

Sponsor: AGO Study Group | Conditions: Platinum Refractory Epithelial Ovarian Cancer, Primary Cancer of the Peritoneum | Phase 2 | Status: COMPLETED